UK cancer drug developer Antisoma says that ATTRACT-2, a Phase III trial testing ASA404 as a second-line treatment for non-small cell lung cancer, is now underway.
This is a single pivotal study designed to support applications to market ASA404 for lung cancer patients who have received one previous round of treatment.
A separate, ongoing pivotal trial, ATTRACT-1, is evaluating the tumor-vascular disrupting agent in patients receiving their first treatment for NSCLC.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze